Siqin Medical Completes Strategic Financing of Tens of Millions of RMB
T-Capital Acts as Exclusive Financial Advisor for This Round
On December 13, 2021, Shenzhen Siqin Medical Technology Co., Ltd. (hereinafter referred to as “Siqin Medical”) announced the completion of a strategic financing of tens of millions of RMB, led by Shandda Capital, with T-Capital acting as the exclusive financial advisor for this round.
The funds from this round will be mainly used to accelerate the company’s R&D of early screening products and business promotion, further promoting Siqin Medical’s product and business development in the field of non-invasive early screening for pan-cancer.
For healthcare companies, in the process of advancing from technology R&D to productization and commercialization, financing is not only related to obtaining funds, but also to how the company clearly presents its technological value, product potential, and future development path to the capital market and industrial investors.
In this transaction, T-Capital provided exclusive financial advisory services to Siqin Medical, assisting the company in advancing this round of strategic financing.
Project Overview
| Item | Information |
|---|---|
| Financing Company | Shenzhen Siqin Medical Technology Co., Ltd. |
| Financing Date | December 13, 2021 |
| Financing Type | Strategic Financing |
| Financing Size | Tens of Millions of RMB |
| Lead Investor | Shandda Capital |
| Financial Advisor | T-Capital |
| Advisor Role | Exclusive Financial Advisor |
| Use of Funds | R&D of early screening products and business promotion |
| Industry | Healthcare / Cancer Early Screening |
| Core Focus | Non-invasive early screening for pan-cancer |
Company and Technology Direction
Siqin Medical is a high-tech biotechnology company focused on non-invasive early screening for pan-cancer.
The company’s pan-cancer non-invasive early screening product, SiKangNing, is used to detect multiple cancers earlier and more accurately by analyzing cell-free DNA fragments, a panoramic map of the cancer genome, and other multi-omics indicators in peripheral blood.
According to the project materials, SiKangNing adopts Siqin Medical’s proprietary multi-dimensional and multi-variable CRS algorithm for comprehensive analysis of relevant biological information, with the product technology direction of improving the accuracy of early cancer screening.
This technological route reflects the trend in the field of early cancer screening from traditional single-indicator detection to multi-omics data analysis and comprehensive algorithm models.
Use of Funds: Accelerating R&D and Business Promotion
The funds from this round of financing are mainly used for two purposes:
1. Accelerating R&D of Early Screening Products
The financing will support Siqin Medical in further advancing the R&D work related to early screening products.
For healthcare companies in the early stages of technology R&D and product commercialization, continuous R&D investment is of great significance for improving products, promoting technology application, and building long-term competitiveness.
2. Promoting Business Promotion
In addition to R&D, this round of financing will also be used for business promotion.
For early cancer screening companies, moving from technology R&D to practical application requires further establishment of product promotion, market expansion, and commercialization capabilities.
Therefore, this round of financing serves both technology R&D and supports the company’s advancement into the business development stage.
T-Capital Acts as Exclusive Financial Advisor
In this round of financing, T-Capital acted as the exclusive financial advisor to Siqin Medical.
Financing for healthcare companies usually involves multiple dimensions such as technology value, product stage, market space, commercialization path, and investor matching.
The value of a professional financial advisor is not only in finding sources of funding, but also in helping the company to:
- Sort out the value of the company and its core assets;
- Clarify financing needs and use of funds;
- Sort out the company’s development logic for investors;
- Screen potential investment institutions;
- Promote communication with investors;
- Assist in financing negotiations;
- Promote transaction execution.
For healthcare companies, the financing process itself is also a systematic process of sorting out corporate value and strategic positioning.
Why Do Healthcare Companies Need Professional Financing Advisors?
The healthcare industry has strong technical professionalism.
A company having excellent technology or products does not mean that investors can quickly understand its investment value.
Healthcare financing usually needs to explain at the same time:
What is the technology → What problem does it solve → What stage is the product in → What is the clinical or application value → Where is the market space → How to promote commercialization → How much funding is needed for the next stage → What goals will the company achieve after financing.
Therefore, healthcare financing needs to effectively connect technical language, business language, and capital market language.
This value sorting is particularly important for innovative drugs, medical devices, in vitro diagnostics, medical diagnostics, early cancer screening, and other healthcare companies.
T-Capital’s Healthcare Financing Services
T-Capital focuses on capital transactions and strategic consulting in the healthcare field, providing companies with financing and capital transaction services for different development stages.
In private financing projects, T-Capital can provide the following advisory services based on the specific situation of the company:
Financing Strategy → Corporate Value Sorting → Investor Matching → Business Communication → Transaction Negotiation → Project Execution
For healthcare companies with innovative technologies, product pipelines, or industrial resources, financing is not necessarily just about finding funds.
More importantly, it is about finding capital and industrial partners that match the company’s development stage, business strategy, and long-term goals.
Healthcare Companies Suitable for Seeking Financing
If your company is in the following stages, a professional financing advisor may have practical value:
- Undergoing Pre-A, Series A, or subsequent financing rounds;
- Planning to introduce strategic investors;
- Having an innovative drug or medical device product pipeline;
- Promoting IVD, medical diagnostics, or early cancer screening projects;
- Needing to raise funds for R&D and commercialization;
- Hoping to introduce industrial capital;
- Looking for long-term strategic partners;
- Preparing for cross-border financing or industrial cooperation.
T-Capital can assist companies in sorting out financing strategies and potential capital cooperation paths based on the company’s stage, financing needs, and industry direction.
From a Single Financing to a Long-term Capital Strategy
A healthcare company’s capital needs usually do not end after a single round of financing.
As the company develops from:
R&D → Product Development → Clinical/Registration → Commercialization → Scale Growth
the company may face different capital needs at different times, including private financing, strategic investment, industrial cooperation, mergers and acquisitions, and cross-border capital transactions.
Therefore, a single financing transaction can also be part of a company’s long-term capital strategy.
For the management of healthcare companies, the more noteworthy questions are not only:
“How much can be raised in this round of financing?”
but also:
“What goals will this round of financing help the company achieve?”
“What type of investors can truly help the company’s next stage of development?”
“How should the company’s future capital path be designed?”
Transaction Highlights
Strategic Financing of Tens of Millions of RMB
Provides funding support for Siqin Medical’s R&D of early screening products and business promotion.
Led by Shandda Capital
This round of financing was led by Shandda Capital.
T-Capital as Exclusive Financial Advisor
T-Capital acted as the exclusive financial advisor for this round of financing, providing financing transaction advisory services to the company.
Focus on Non-invasive Early Screening for Pan-Cancer
Siqin Medical focuses on the field of non-invasive early screening for pan-cancer, and its core product, SiKangNing, adopts multi-omics analysis and a multi-dimensional and multi-variable CRS algorithm.
If Your Company is Looking for Financing
If you are running a healthcare company and are planning your next round of financing, introducing strategic investors, or looking for industrial partners, you can communicate with T-Capital.
We are particularly focused on:
Innovative Drugs | Medical Devices | Medical Diagnostics | IVD | Cancer Early Screening | High-value Consumables | Healthcare Services | AI + Healthcare | Biotechnology
We can discuss suitable capital transaction paths for your company based on its development stage, product and technology characteristics, financing goals, and long-term strategy.
Communicate with T-Capital
If you are considering financing, you are welcome to contact us and introduce your company, financing stage, and main needs.
T-CAPITAL
Healthcare Industry Capital Transactions and Strategic Consulting